T. Rowe Price Associates
CABA icon

T. Rowe Price Associates’s Cabaletta Bio CABA Stock Holding History

T. Rowe Price Associates’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.7M Buy
4,418,674
+3,976,397
+899% +$13.1M ﹤0.01% 1253
2026
Q1 		$1.19M Sell
442,277
-651,682
-60% -$1.81M ﹤0.01% 2068
2025
Q4 		$2.4M Sell
1,093,959
-200,990
-16% -$498K ﹤0.01% 1672
2025
Q3 		$3.03M Sell
1,294,949
-892,090
-41% -$1.53M ﹤0.01% 1567
2025
Q2 		$3.33M Buy
2,187,039
+1,697,718
+347% +$2.65M ﹤0.01% 1431
2025
Q1 		$678K Sell
489,321
-34,766
-7% -$74.1K ﹤0.01% 2137
2024
Q4 		$1.19M Sell
524,087
-28,705
-5% -$101K ﹤0.01% 1894
2024
Q3 		$2.61M Sell
552,792
-29,483
-5% -$171K ﹤0.01% 1522
2024
Q2 		$4.36M Sell
582,275
-30,123
-5% -$369K ﹤0.01% 1262
2024
Q1 		$10.4M Buy
612,398
+84,633
+16% +$1.82M ﹤0.01% 1101
2023
Q4 		$12M Buy
527,765
+512,450
+3,346% +$8.62M ﹤0.01% 1058
2023
Q3 		$234K Buy
15,315
+2,724
+22% +$37.2K ﹤0.01% 2444
2023
Q2 		$163K Buy
+12,591
New +$137K ﹤0.01% 2589

Other funds holding CABA

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

T. Rowe Price Associates's CABA Position: Q2 2026 in Review

T. Rowe Price Associates increased its Cabaletta Bio (CABA) stake by 899% in Q2 2026, buying an estimated $13.1M and bringing the position to 4,418,674 shares worth $13.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1253.

T. Rowe Price Associates first reported a position in CABA in Q2 2023 and has held it in 13 quarters since. 140 funds tracked by Wall St. Rank hold CABA as of Q2 2026.

  • T. Rowe Price Associates held 4,418,674 shares of Cabaletta Bio worth $13.7M as of Q2 2026.
  • T. Rowe Price Associates bought 3,976,397 Cabaletta Bio shares in Q2 2026, an estimated $13.1M.
  • Cabaletta Bio made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1253 holding.
  • T. Rowe Price Associates first reported a position in Cabaletta Bio in Q2 2023 and has held it in 13 quarters since.
  • 140 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.